Bristol Myers Squibb: Opdivo Plus Yervoy Didn't Meet Primary Endpoint in Cancer Study

By Mary de Wet

Bristol Myers Squibb Co. said part of its study of Opdivo plus Yervoy to treat patients with localized renal cell carcinoma didn't meet its primary endpoint of disease-free survival.

Part A of the Phase 3 trial was to evaluate using Opdivo in combination with Yervoy in patients who have undergone surgery to remove part or all of a kidney and who are at moderate to high risk of relapse. Part B of the trial will look at using Opdivo alone, the company said.

Opdivo and Opdivo-based combinations have demonstrated clinical benefits for several renal cell cancer patient groups, Bristol Myers said.

"We are disappointed that the final analysis of CheckMate -914 Part A did not show this same benefit for the post-surgical treatment of patients with localized RCC," said Dr. Dana Walker, vice president and development program lead of genitourinary cancers. "Nonetheless, we are dedicated to continuing research and advancing cancer care for all patients with RCC."

Write to Mary de Wet at [e-mail]

(END) Dow Jones Newswires

July 29, 2022 07:35 ET (11:35 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.